EUVIMEDEUVIMED entdecken
Crossref

Impact of omitting the intravenous heparin bolus on outcomes of leadless pacemaker implantation

Jingwen Huang, Neal K Bhatia, Michael S Lloyd iD, Stacy Westerman, Anand Shah, David Delurgio iD, Anshul M Patel, Christine Tompkins, Mikhael F El-Chami iD, Faisal M Merchant

Journal of Cardiovascular Electrophysiology · 2024

DOI: 10.1111/jce.16284 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2024. Verfasst von Jingwen Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Heparin, Pacemaker, Artificial, Anticoagulants, Cardiac Pacing, Artificial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Early guidance recommended a bolus of intravenous heparin at the beginning of leadless pacemaker (LP) implantation procedures. However, due to concern about bleeding complications, more recent practice has tended toward omitting the bolus and only running a continuous heparin infusion through the introducer sheath. The impact of omitting the heparin bolus on procedural outcomes is not clear.

Methods

We reviewed all Medtronic Micra LP implants at our institution from 9/2014 to 9/2022. The decision to bolus with heparin was at operator discretion.

Results

Among 621 LP implants, 326 received an intravenous heparin bolus, 243 did not, and 52 patients were excluded because heparin bolus status could not be confirmed. There was a trend toward more frequent omission of the heparin bolus with more recent implants. Median follow‐up after LP implant was 14.3 (interquartile range [IQR]: 8.4–27.9) months. There was no difference between heparin bolus and no bolus groups in the number of device deployments/recaptures (1.42 ± 0.81 vs. 1.31 ± 0.66, p = .15). Implant‐related adverse events were also similar between heparin bolus and no bolus groups: access‐site hematoma requiring intervention (7 vs. 5, p = .99), pseudoaneurysm (1 vs. 1, p = .99), cardiac perforation (1 vs. 1, p = .99), intraprocedural device thrombus formation (2 vs. 4, p = .41), 30‐day rehospitalization (21 vs. 15, p = .98), and 30‐day all‐cause mortality (16 vs. 14, p = .70). There was one additional nonfatal cardiac perforation in a patient who was excluded due to unknown heparin bolus status. Regarding device electrical parameters between heparin bolus and no bolus groups, there were no significant differences at the time of implant: pacing capture threshold 0.5 ± 0.4 vs. 0.5 ± 0.3, p = .10; pacing impedance 739.9 ± 226.4 vs. 719.1 ± 215.4, p = .52; R wave sensing 11.7 ± 5.7 vs. 12.0 ± 5.4, p = .34). Long‐term device performance was also similar between groups.

Conclusion

Omission of the systemic heparin bolus at the time of LP implantation appears safe in appropriately selected patients. Heparin bolus may still be considered in long cases requiring multiple device deployments or in patients at high risk for thrombotic complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HeparinPacemaker, ArtificialAnticoagulantsCardiac Pacing, ArtificialHumansMaleAgedFemaleTreatment OutcomeRetrospective StudiesTime FactorsRisk FactorsAged, 80 and overMiddle AgedDrug Administration ScheduleProsthesis ImplantationProsthesis Design

Stichwörter der Autor:innen

clinical:implantable devices–pacemaker‐bradyarrhythmias

Substanzen

HeparinAnticoagulants

Autor:innen und Institutionen

  • Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia, USA.

ORCID-Profile: Michael S Lloyd, David Delurgio, Mikhael F El-Chami

Zitieren

APA

Huang, J., Bhatia, N. K., Lloyd, M. S., Westerman, S., Shah, A., Delurgio, D., Patel, A. M., Tompkins, C., El-Chami, M. F., & Merchant, F. M. (2024). Impact of omitting the intravenous heparin bolus on outcomes of leadless pacemaker implantation. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.16284

Vancouver

Huang J, Bhatia NK, Lloyd MS, Westerman S, Shah A, Delurgio D, et al. Impact of omitting the intravenous heparin bolus on outcomes of leadless pacemaker implantation. Journal of Cardiovascular Electrophysiology. 2024. doi:10.1111/jce.16284

BibTeX
@article{Huang2024,
  author = {Huang, Jingwen and Bhatia, Neal K and Lloyd, Michael S and Westerman, Stacy and Shah, Anand and Delurgio, David and Patel, Anshul M and Tompkins, Christine and El-Chami, Mikhael F and Merchant, Faisal M},
  title = {Impact of omitting the intravenous heparin bolus on outcomes of leadless pacemaker implantation},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2024},
  doi = {10.1111/jce.16284}
}
Kostenlos starten →